Werewolf Therapeutics, Inc. cash flow to debt ratio of -639.02% indicates that the company cannot generate enough cash to cover its debt over time. This level indicates weak financial health.

Werewolf Therapeutics, Inc.'s free cash flow has decreased 6.82% from $-56.44M last year to $-60.29M, signaling decreasing performance

Werewolf Therapeutics, Inc.'s debt to equity ratio is 0.00, which means that the company's assets are healthy financed, signaling financial stability.

Werewolf Therapeutics, Inc.'s debt has decreased relative to shareholder equity from 0.51 last year to 0.00 today, signaling strengthened financials

Werewolf Therapeutics, Inc. has a net cash position, so leverage is healthy.

Werewolf Therapeutics, Inc.'s interest coverage ratio is -5.62, which means that the company struggles to meet interest obligations, signaling financial risk.

Werewolf Therapeutics, Inc.'s profit margin has increased (-95.59%) in the last year from -3.74K% to -164.82%, signaling increasing performance

Werewolf Therapeutics, Inc.'s short-term assets of $58.59M exceed its short-term liabilities of $36.15M

Werewolf Therapeutics, Inc.'s return on assets of 0.00% is lower than the 5.00% threshold, indicating inefficient asset utilization

Werewolf Therapeutics, Inc.'s return on equity of -166.98%, is lower than 15.00%, indicating bad performance

Werewolf Therapeutics, Inc.'s operating cash flow is lower than its net income, indicating that earnings may not be fully backed by cash generation

Werewolf Therapeutics, Inc. had positive net income in only 0 out of 5 years, indicating unstable earnings

Werewolf Therapeutics, Inc. has negative free cash flow, indicating the company is burning cash rather than generating it

Werewolf Therapeutics, Inc. has negative free cash flow, indicating cash burn

Werewolf Therapeutics, Inc.'s yearly earnings has increased -13.75% since last year from $-70.52M to $-60.82M, signaling increasing performance

Werewolf Therapeutics, Inc.'s yearly revenue has decreased 100.00% since last year from $1.89M to $0.00, signaling decreasing performance

ROIC -156.97% (Source: FMP key-metrics). Below the 5% partial-credit threshold. Score: 0 of 2. The 5% and 10% cutoffs anchor to typical US weighted-average cost of capital. Below 5% indicates the company is not generating returns above its likely cost of capital under this definition of invested capital. Invested capital here includes equity, non-current liabilities (pension obligations, deferred taxes, lease obligations), and short-term debt. Cash is not subtracted. Companies with substantial float, lease portfolios, or cash holdings will score lower under this definition than under narrower operating-capital definitions. See methodology.

Werewolf Therapeutics, Inc.'s 3-year revenue CAGR of -100.00% is negative, indicating declining revenue over the past 3 years

Werewolf Therapeutics, Inc. had revenue growth in 3 out of 5 years, indicating consistent revenue performance

Werewolf Therapeutics, Inc. had positive ROE in only 0 out of 5 years, indicating inconsistent returns on equity

Werewolf Therapeutics, Inc. has insufficient data to evaluate this check.

Werewolf Therapeutics, Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

Werewolf Therapeutics, Inc. is overvalued relative to its fair value price of 0.00 based on EBITDA multiple model

Werewolf Therapeutics, Inc. has negative or missing EBITDA, making EV/EBITDA ratio unreliable

Werewolf Therapeutics, Inc. has insufficient data to evaluate this check.

Werewolf Therapeutics, Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

Werewolf Therapeutics, Inc. has a price-to-book ratio of 1.14x, which is below the 5.00x threshold, indicating reasonable valuation relative to its book value

Werewolf Therapeutics, Inc. has a price-to-sales ratio of 0.88x, which is below the 8.00x threshold, indicating reasonable valuation relative to its revenue